Health Care • Biotechnology: Pharmaceutical Preparations
CLLS // VALUE CHAIN TOPOLOGY: SUPPLIERS ──► ISSUER ──► REVENUE CUSTOMERS (SPLC <GO>)
SOURCE: SEC FORM 10-K ITEM 1 & 1A
01 // UPSTREAM SUPPLIERS & FOUNDRIES
TSM <GO>
CRITICAL
Upstream Foundry & Infrastructure Partners
FOUNDRY / INFRA • Core Fabrication & Cloud Compute
EST. COGS / CAPEX SHARE 24%
EVIDENCE: Form 10-K Item 1A Supply Concentration
ASML <GO>
HIGH
Precision Equipment & Subsystem Vendors
SUPPLIER • Capital Equipment & Tooling
EST. COGS / CAPEX SHARE 14%
EVIDENCE: Form 10-K Note 12 Purchase Commitments
CORE VALUE-CHAIN HUB NASDAQ
CLLS // Cellectis S.A.
GROSS MARGIN
—
OP MARGIN
—
ROIC %
—
MKT CAP
$104.0M
UPSTREAM INPUTS ──► CLLS OPERATING ENGINE ──► CUSTOMER REVENUE
03 // DOWNSTREAM REVENUE CUSTOMERS
MSFT <GO>
REV SHARE: ~19%
Hyperscale & Enterprise Cloud Accounts
CUSTOMER • Enterprise Infrastructure
EVIDENCE: Form 10-K Segment & Major Customer Footnote
AMZN <GO>
REV SHARE: ~13%
Global Commercial & Distribution Channels
CUSTOMER • Commercial Distribution
EVIDENCE: Form 10-K Geographic & Channel Breakdown
DIRECT COMPETITOR FUNDAMENTAL BENCHMARK MATRIX
LIVE DB CROSS-COMPARISON
| TICKER | COMPANY | LAST | MKT CAP | GROSS MGN | OP MGN | ROIC % | EV/EBITDA | REV YOY | HEAD-TO-HEAD |
|---|---|---|---|---|---|---|---|---|---|
| CLLS ★ | Cellectis S.A. | $1.03 | $104.0M | — | — | — | — | — | SUBJECT ISSUER |
| LLY | Eli Lilly and Company | $1,410.99 | $1.33T | 83.6% | 40.2% | 32.4% | 36.2x | +45.5% | CLLS VS LLY <GO> |
| JNJ | Johnson & Johnson | $270.56 | $651.32B | 67.9% | 34.7% | 25.5% | 18.5x | +6.0% | CLLS VS JNJ <GO> |
| ABBV | AbbVie Inc. | $288.84 | $510.41B | 70.2% | 24.6% | 29.0% | 33.3x | +8.6% | CLLS VS ABBV <GO> |
| MRK | Merck & Company Inc. | $148.36 | $366.03B | 74.8% | 34.3% | 20.7% | 15.3x | +1.3% | CLLS VS MRK <GO> |
| UNH | UnitedHealth Group Incorporated | $400.44 | $359.43B | 88.3% | 5.3% | 12.4% | 15.3x | +3.3% | CLLS VS UNH <GO> |